Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer

Expert Opinion on Biological Therapy

Volumn 14, Issue 4, 2014, Pages 527-534

  Garland, Suzanne M ^a,b,c   Brown, Darron R ^d  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AOGIN (Asia Oceania Research Organization on Genital Infections and Neoplasia)   (Australia)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cervical cancer; Genital warts; Human papillomavirus; Prophylactic vaccine

Indexed keywords

WART VIRUS VACCINE;

CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CHEMISTRY; CHEMOPROPHYLAXIS; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; HUMAN; IMMUNITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LEGAL ASPECT; NAUSEA; PHARMACODYNAMICS; REVIEW; TUMOR IMMUNITY; UTERINE CERVIX CANCER;

ANIMALS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; LEGISLATION, DRUG; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRODUCT SURVEILLANCE, POSTMARKETING; UTERINE CERVICAL NEOPLASMS;

EID: 84896112874     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.880418     Document Type: Review

References (51)

1. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347(21):1645-51
2. Crum CP. The beginning of the end for cervical cancer? N Engl J Med 2002;347(21):1703-5
3. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013;346:f2032
4. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377(9783):2085-92
5. Gertig DM, Brotherton JM, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011;8(2):171-8
6. Garland SM, Skinner SR, Brotherton JM. Adolescent and young adult HPV vaccination in Australia: achievements and challenges. Prev Med 2011;53(Suppl 1):S29-35
7. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356(19):1928-43 .
8. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. NEJM 2007;356(19):1915-27
9. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009;2(10):868-78
10. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011;364(5):401-11
11. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365(17):1576-85
12. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-917
13. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118(5):2135-45
14. Olsson S, Villa L, Costa R, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25(26):4931-9
15. Roberts JN, Buck CB, Thompson CD, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007;13(7):857-61
16. Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009;200(2):166-71
17. Carter JJ, Wipf GC, Madeleine MM, et al. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol 2006;80(10):4664-72
18. Pastrana DV, Buck CB, Pang YY, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2012;321(2):205-16
19. Smith JF, Kowalski R, Esser MT, et al. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil-, a vaccine for human papillomavirus types 16, 18, 6, and 11. Hum Vaccin 2008;4(2):134-42
20. Brown DR, Garland S. Cervical cancer vaccines. Principals Pract Oncol 2008;22(4):1-12
21. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008;26(52):6844-51
22. WHO, (World Health Organisation). Guidelines on Non Clinical Evaluation of Vaccines: WHO Technical Report Series; 2003
23. CHMP (Committee for Medical Products for Human Use). Guideline on Clinical Evaluation of New Vaccines. Report; 2006
24. Lowy DR, Frazer IH. Prophylactic human papillomavirus vaccines. JNCI Monogr 2003;2003(31):111-16
25. Pagliusi SR, Teresa AM. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23(5):569-78
26. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493
27. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Nat Cancer Inst 2010;102(5):325-39
28. Munoz N, Manalastas RJr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009;373(9679):1949-57
29. Castellsagué X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 - 45 years of age. Br J Cancer 2011;105(1):28-37
30. Tabrizi SN, Brotherton JML, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012;206(11):1645-51
31. Tabrizi SN, Brotherton JML, Kaldor JM, et al. Human papillomavirus prevalence following a national vaccination program [abstract SS22-1]. EUROGIN; Florence Italy; 2013
32. Ali H, Guy RJ, Wand H, et al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis 2013;13(1):1-6
33. Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013;11(1):227
34. Australian Government. HPV school vaccination program. Available from: http://hpv.health.gov.au
35. HPV vaccine uptake 2011 to 2012: provisional data for 1 September 2011 to 31 August 2012. Public Health England. Available from: https://www.gov.uk/ government/organisations/public-healthengland Published 23 September 2013
36. Shearer BD. HPV Vaccination: understanding the impact of HPV disease. Purple Paper 2011;34:18
37. Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and post licensure vaccine safety monitoring, 2006-2013 - United States. MMWR Morb Mortal Wkly Rep 2013;62(29):591-5
38. Statens Serum Institute. HPV Vaccination - Coverage 2012. EPI NEWS - Statens Serum Institut 2013; 20
39. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012;102(5):833-5
40. Markowitz LE, Hariri S, Unger ER, et al. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010;28(30):4731-7
41. Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009;114(6):1179-88
42. Agorastos T, Chatzigeorgiou K, Brotherton JM, et al. Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 2009;27(52):7270-81
43. Dana A, Buchanan KM, Goss MA, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009;114(6):1170-8
44. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302(7):750-7
45. Buttery JP, Madin S, Crawford NW, et al. Mass psychogenic response to human papillomavirus vaccination. Med J Aust 2008;189(5):261-2
46. Clements CJ. Mass psychogenic illness after vaccination. Drug Saf 2003;26(9):599-604
47. Crawford NW, Clothier HJ, Elia S, et al. Syncope and seizures following human papillomavirus vaccination: a retrospective case series. Med J Aust 2011;194(1):16
48. Barbaro B, Brotherton JM, Gertig DM. Human papillomavirus vaccination and cervical cancer screening by socioeconomic status, Victoria. Med J Aust 2012;196(7):445
49. Luxembourg A. An overview of the 9-valent HPV L1 virus-like particle vaccine clinical development program [abstract SS8-3]. EUROGIN; 3 - 6 November 2013; Florence Italy
50. Joura E. Efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16 to 26 -year-old women [abstract SS 8-4]. EUROGIN; 3 - 6 November 2013; Florence, Italy
51. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30(Suppl 5):F123-F38